CHA University Bundang Medical Center
Seongnam-si, Gyeonggi-do, 13520, South Korea
NCT Number: NCT07239453
This study is to compare pharmacokinetics and safety profiles of DA-2902 and DA-2902-R in healthy adult subjects
Looking for future studies?
Notify Me19 year–44 year
All sexes
Interventional
Phase 1
Seongnam-si, Gyeonggi-do, 13520, South Korea
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
single dose administration (DA-2902 one tablet once a day)
single dose administration (DA-2902-R one tablet once a day)
Time frame: pre-dose ~ 72 hr of pose-dose
Time frame: pre-dose ~ 72 hr of post-dose
Dong-A ST Co., Ltd.
Industry
An Open-Label, Randomized, Single Oral Dose, Two-Sequence, Two-Period, CrossovSer Bioequivalence Study of "DA-2902" and "DA-2902-R" in Healthy Adults Under Fed Conditions
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05765422
Communicable Diseases, Disease Attributes
Nice, France
View Trial DetailsNCT05286203
Communicable Diseases, Disease Attributes
San Francisco, California, United States
View Trial DetailsNCT07092046
Anesthesia Circuit, Anesthesia Equipment Bacterial Contamination
Ankara, Turkey (Türkiye)
View Trial DetailsNCT05286879
Behavior, Chemically-Induced Disorders
New Haven, Connecticut, United States
View Trial Details